Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 15Breast 3Plasma cell 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Endometrial Neoplasms 2Ovarian Neoplasms 1Lymphoma, Follicular 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × copanlisib × Gynecologic × Clear all
NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 10 charts
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT04750941 2025-03-04

Study of Copanlisib and Ketogenic Diet

Columbia University

Phase 2 Terminated
1 enrolled 9 charts
GynecologicLymphoid

Lymphoma, Follicular, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡